Frost & Sullivan takes no responsibility for the incorrect information supplied to us by manufacturers or users.
Quantitative market information is based primarily on interviews and therefore, is subject to fluctuation.
Frost & Sullivan Research Services are limited publications containing valuable market information provided to a select group of customers in response to orders. Our customers acknowledge, when ordering, that Frost & Sullivan Research Services are for customers’ internal use and not for general publication or disclosure to third parties.
No part of this Research Service may be given, lent, resold, or disclosed to non-customers without written permission.
Furthermore, no part may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the permission of the publisher.
We hereby certify that the views expressed in this research service accurately reflect our views based on primary and secondary research with industry participants, industry experts, end users, regulatory organizations, financial and investment community, and other related sources.
In addition to the above, our robust in-house forecast & benchmarking models along with the Frost & Sullivan Decision Support Databases have been instrumental in the completion and publishing of this research service.
We also certify that no part of our analyst compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this research service.
Setting the Scene Outlook for Healthcare Industry from 2010-12 Global Healthcare Market : 2009
US and Europe were impacted in a major way by global crisis
Asia also slowed down but not as much as the West
Valuations were low and M&A was high, many smaller Biotech companies struggled
Major organizational restructuring occurred, along with portfolios being reassessed
Global Healthcare Market : 2010-12
Recovery of the markets to a large extent with strong growth in Asia
Start of major patent expiries
M&A activity down in the West but could be important in Asia, restructuring will continue
Asia becoming increasingly important as a market and outsourcing hub
5Ps to drive market: Preventive, Preemptive, Personalized, Predictive, Personal Responsibility
Source: Frost & Sullivan.
Global vs. APAC: The New Frontier By 2012 APAC expected to be close to 27% of global market Source: Frost & Sullilvan ,2010 ) 23.9% 27.2% 23.2% 26.4% CAGR 12.2% CAGR 6.47%
By 2015 APAC could represent ~40% of global market!
Source: Frost & Sullivan Rest of the World APAC Global & APAC Healthcare Revenues US$ Bn, 2009-2012
Asia is however transitioning Moving toward a Multi–Polar World Order Source: Frost & Sullilvan ,2010 ) Asia Pacific Market : 2009
Slowing down of GDP in mature markets – Japan and Australia took a big hit
Global consolidation left a difficult mess for integration on a local level – job losses and portfolio realignment
Price cutting and playing the margins game
The bubble burst for Medical Tourism
Asia started to set up infrastructure for offshoring and outsourcing for US/EU companies
Asia Pacific Market : 2012
A shift in the center of the world economically and strategically to Asia
Asia to move from export led development to consumption led growth
APAC the fastest growing pharma market and API production hub
Increased government attention to primary and community based healthcare .
Increased use of mobile technology in healthcare service delivery
2010 : Malaysia Innovation and Creativity year
Source: Frost & Sullivan.
Aged Population , 65+ cohort is more than 20% (2008) Japan Household Financial Assets ~ US $ 16 Trillion (Sept. 2009) ** *Source MHLW, METI Source: Diabetes Australia Japan-Aging Society, Increased Economic Wealth Seizing Growth Opportunity in a deflationary environment WATAMI GROUP COMMONS 30 FUND
Source: Frost & Sullivan. Patient Adherence (Role of New Therapies) Re-imbursement based On value (Role of cost-effective devices) Provider focus in under-served areas ( Role of IT) Japan Healthcare Industry –SWOT Analyses Emerging Paradigms
Universal Mandatory Insurance
Healthcare expenditure lower
compared to OECD countries
Highly developed infrastructure
and well trained & dedicated medical staff
Focus on short term cost constraint rather
than value for patients
Duplication and fragmentation of services
-Multi tiered distribution system
Slow registration/approval process
Rapidly Aging Population
Increasing economic wealth
Low custom duties/tariffs
Inadequate services in rural areas
Inefficient Physician usage
Dependency on imports slows down
Failure to adopt locally developed
principles like TQM
Weaknesses Strengths Opportunities Threats
In-depth Sectoral Analysis, APAC and South Korea
APAC Pharmaceuticals Market Earlier diagnosis improves disease management and length of therapy Note: All figures are rounded; the base year is 2009. Source: Frost and Sullivan Market Drivers Market Restraints
Long term use of multiple and specialized drugs for the ageing population
Government support for generics and biosimilars
Enhanced diagnosis and management in oncology, cardiovascular, pain etc
Cardiovascular disorders, alimentary canal & metabolism and general anti-infectives remained the top selling therapeutic categories in Japan, registering 2008 sales of $14.6bn, $9.6bn and $6.5bn respectively.
Prevalence of diabetes : 2010 : ~8 mn. Potential for diagnosis and treatment as nearly 20% of cases are undiagnosed
Bio-pharmaceuticals, Vaccines Cardiovascular and metabolic diseases, Generics Oncology
Japan Oncology market in 2009 : ~ US$ 1 0 Billion; CAGR ~ 14-15%
Growth from early diagnosis of cancers and specialised therapies
Targeted therapies (Avastin etc)
Adjuvant therapies (Xeloda etc)
Supportive therapies (Neutrogin etc)
Top Growth Opportunities : Japan Pharmaceuticals and Biotech Market
2009 : biopharmaceuticals identified as a growth engine for the Japanese pharma sector. Targeted therapies and antineoplastics & immunomodulating agents are expected to record the highest growth with CAGR of 19.8% and 10.1%, respectively, over the forecast period.
Somatropin BS formed the first biosimilar to launch in Japan. Cervarix, Prevenar and Januvia formed the most awaited vaccine drugs to receive Japanese approval in 2009.
Vaccines offer tremendous potential (MMR, Inactivated Polio, Rotavirus). 4% of global sales.
Source: Frost & Sullivan.
APAC Medical Equipment Market Transition to a mindset of monitoring 59.4 65.4 72.0 79.4 Note: All figures are rounded; the base year is 2009. Source: Frost and Sullivan Market Drivers
Safety, accuracy, efficiency, cost
Automation and integration with information systems
Emphasis on early detection and monitoring
Silver industry requirements
Regulatory and reimbursement hurdles
Inadequate distribution networks
Inadequate training on and compliance to new technology
Source: Frost & Sullivan. Medical Equipment Revenues, US$ Bn, 2009-2012
Japan Medical Equipment Market Focus on technology that provides integrated medical care Medical Equipment Revenues, US$ Bn, 2009-2012 Market Drivers Market Restraints
Demand for advanced and innovative medical equipment
Increased prevalence of chronic and lifestyle diseases
Increasing Funding Gap (~US$ 200 Billion by 2020?)
Strong reliance on imports in relation to domestic manufacture
Demand for Orthopedic, Gastro-intestinal, Urology, Cardiovascular, Neurosurgery and Pulmonary devices is being driven by increased prevalence of chronic and age related diseases .
Demand for devices used in ICU and related departments is growing at a slower place (bed penetration is less than 1%)
Increased demand for POCT and laboratory automation products
Demand for Diabetes management tests, HbA1c, heart failure detection BNP, including NT-proBNP and lipid metabolism management index LDL-C has been increasing steadily. Influenza test kit was in enormous demand in 2009
Demand for personalized medicine/testing has started to ramp up
Note: All figures are rounded; the base year is 2009. Source: Frost and Sullivan *Healthcare IT includes: Software, Hardware, IT services and Lifesciences IT Asia Pacific Lifesciences and Health IT Market* Interoperability challenges hinder adoption Market Drivers Market Restraints
Strong and sustained demand for healthcare services
Consumer demand for quality and access to information
Growing demand for patient centered healthcare services and systemized healthcare organization management through the implementation of advanced healthcare systems
Japan market 2010 ( Outreach and Remote care delivery: Home Health and Tele-Medicine/Tele-Health) : ~US$ 134 mn; CAGR ~2%
The popularity of this segment can be contributed to the aging population, lack of hospital bed capacity and the increased need for home care for patients with chronic conditions. The country is also encouraging initiatives to increase communication between physician, pharmacies and patient for delivery of orders, prescriptions and payment.
Japan is moving towards a government-centered EHR system. The installation of EHR systems, especially for clinical use such as medical digital imaging reference functions are increasing in clinics and hospitals.
Summary : Best Opportunity Analysis APAC and South Korea
Where to place your bets in Japan : 2010- 2012 Source: Frost & Sullivan. Advanced Image Processing Surgical Planning Oncology Drugs Time Growth Generics Personalised Testing EMR/EHR Medical Imaging (CRA, MRA etc) INNOVATION TRIGGER SUPER GROWTH NORMALISATION LEADERSHIP Vaccines General Surgery Cardiovascular Drugs
Global thought leader exclusively focused on addressing client growth strategies and plans – Team actively engaged in researching and developing of growth models that enable clients to achieve aggressive growth objectives.
Cover the broad spectrum of industries and technologies to provide clients with the ability to look outside the box and discover new and innovative ideas.
32 global offices ensure that clients receive a global coverage/perspective based on regional expertise.
360 o Perspective
Proprietary TEAM Methodology integrates all 6 critical research methodologies to significantly enhance the accuracy of decision making and lower the risk of implementing growth strategies.
Continuously monitor changing technology, markets and economics and proactively address clients growth initiatives and position.
Working closely with client Growth Teams – helping them generate new growth initiatives and leverage all of Frost & Sullivan assets to accelerate their growth.
Frost & Sullivan’s proprietary TEAM methodology , ensures that clients have complete “360 Degree Perspective” from which to drive decision-making. T echnical, E conometric, A pplication, and M arket information ensures that clients have a comprehensive view of industries, markets and technology.
T echnical Real-time intelligence on technology, including emerging technologies, new R&D breakthroughs, technology forecasting, impact analysis, groundbreaking research, and licensing opportunities. E conometric In-depth qualitative and quantitative research focused on timely and critical global, regional, and country specific trends, including the political, demographic, and socioeconomic landscapes. A pplication Insightful strategies, networking opportunities, and best practices that can be applied for enhanced market growth; interactions between the client, peers, and Frost & Sullivan representatives that result in added value and effectiveness. M arket Global and regional market analysis, including drivers and restraints, market trends, regulatory changes, competitive insights, growth forecasts, industry challenges, strategic recommendations, and end-user perspectives.